Biogen

Regulus said it was able to develop its miRNA extraction and profiling technology to meet the quality specifications set out by its partner.

The partners will build a new sequencing facility at Columbia to help uncover new drug targets for the drug-developer.

Biogen Idec has hired Olivier Danos as senior VP of gene therapy. Danos will report to Douglas Williams, executive VP of R&D at Biogen Idec. At Biogen Idec, he will be in charge of the gene therapy research group, which develops new technologies for gene transfer and genome engineering.

NEW YORK (GenomeWeb) – Officials from Regulus Therapeutics this week provided updates for the company's two lead drug candidates, stating that a Phase I study of its hepatitis C treatment RG-101 is set to yield key data in the next few months, while the preclinical Alport syndrome therapy RG-012

NEW YORK (GenomeWeb) – Regulus Therapeutics today announced a new collaborative agreement with Biogen Idec to identify microRNAs for multiple sclerosis.

NEW YORK (GenomeWeb News) – Scientists at the Whitehead Institute will use $5.3 million over the next three years from Biogen Idec to pursue research projects involving genomics, genetics, immunology, neurology, developmental biology, and other approaches.

David Flannery, a pediatric geneticist, is the new medical director of the American College of Medical Genetics and Genomics.

Regulus Therapeutics this week announced that it has received a milestone payment from Biogen Idec as part of the companies' ongoing partnership to identify microRNA biomarkers for multiple sclerosis.

Originally published Oct. 8

Isis Pharmaceuticals this week announced that it had formed a strategic alliance with Biogen Idec to develop antisense-based treatments for neurological disorders.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.